scholarly journals Visual Loss following Daily Dose Regimen of Anti Tubercular Treatment

2020 ◽  
Vol 31 (2) ◽  
Author(s):  
Silni Chandra
Keyword(s):  
Dose Regimen ◽  
Visual Loss ◽  
Daily Dose ◽  
Daily Dose Regimen

Clinical and microbiological outcomes in treatment of men with non-gonococcal urethritis with a 100-mg twice-daily dose regimen of sitafloxacin

2012 ◽  
Vol 18 (3) ◽  
pp. 414-418 ◽  
Author(s):  
Shin Ito ◽  
Mitsuru Yasuda ◽  
Kensaku Seike ◽  
Takashi Sugawara ◽  
Tomohiro Tsuchiya ◽  
...  
Keyword(s):  
Dose Regimen ◽  
Gonococcal Urethritis ◽  
Daily Dose ◽  
Daily Dose Regimen

Treatment of hyperthyroidism with a small single daily dose of methimazole

1988 ◽  
Vol 119 (1) ◽  
pp. 139-144 ◽  
Author(s):  
Yasuo Mashio ◽  
Mutsuo Beniko ◽  
Akemi Ikota ◽  
Hiroaki Mizumoto ◽  
Haruhiko Kunita
Keyword(s):  
Divided Dose ◽  
Dose Regimen ◽  
Single Daily Dose ◽  
Once Daily ◽  
Daily Dose ◽  
The Mean ◽  
Time Required ◽  
Daily Dose Regimen ◽  
Mean Time ◽  
Immunoglobulin Levels

Abstract. A prospective randomized trial with the conventional divided doses (10 mg 3 times daily, N = 29) and a small single daily dose (15 mg once daily, N = 25) of methimazole for the treatment of Graves' hyperthyroidism was performed. Within 8 weeks, almost 80% of the patients in both groups became euthyroid. The mean time required to achieve the euthyroid state was 6.0 ± 2.8 and 6.0 ± 3.8 weeks, respectively. TSH binding inhibitor immunoglobulin was found in about 90% of the patients in both groups before methimazole treatment. However, a gradual fall of its levels was observed in nearly all patients after treatment. There was no difference in the mean levels of TSH binding inhibitor immunoglobulin between the two groups during therapy. We conclude that the single daily dose regimen of 15 mg of methimazole will control Graves' hyperthyroidism in most patients, and TSH binding inhibitor immunoglobulin levels decrease in this regimen in the same way as with the conventional divided dose regimen (10 mg 3 times daily).

scholarly journals Once-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial

2015 ◽  
pp. 137
Author(s):  
Guido Haenen ◽  
Jiska Balk ◽  
Ron Peters ◽  
Aalt Bast ◽  
Wim van der Vijgh ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dose Regimen ◽  
Once Daily ◽  
Daily Dose ◽  
Daily Dose Regimen

The Antihypertensive Effect of Verapamil in Twice and Thrice Daily Dose Regimens. A Randomized, Double-Blind, Crossover Trial

1983 ◽  
Vol 11 (3) ◽  
pp. 190-193 ◽  
Author(s):  
B Hedbäck ◽  
K Parment
Keyword(s):  
Dose Regimen ◽  
Crossover Trial ◽  
Antihypertensive Effect ◽  
Morning Dose ◽  
Double Blind ◽  
Daily Dose ◽  
The Mean ◽  
Daily Dose Regimen ◽  
Blind Crossover Study ◽  
Double Blind Crossover Study

The antihypertensive effect of verapamil 200 mg b.i.d. was compared with that of verapamil 120 mg t.i.d. in a double-blind crossover study in eight out-patients with essential hypertension. The mean supine blood pressure measured before the morning dose was 150/87 mm Hg in patients treated with verapamil 200 mg b.i.d. and 151/87 mm Hg in those treated with verapamil 120 mg t.i.d. The recently reported prolonged half-life and accumulation of verapamil during steady-state conditions explains the lasting antihypertensive effect with the twice-daily dose regimen. Such a twice daily dose regimen is presumed to be more convenient to the patients and thus improve their compliance.

scholarly journals Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves’ Hyperthyroidism: A Randomized Controlled Study

2017 ◽  
Vol 2017 ◽  
pp. 1-6 ◽  
Author(s):  
Sutin Sriussadaporn ◽  
Wanwaroon Pumchumpol ◽  
Raweewan Lertwattanarak ◽  
Tada Kunavisarut
Keyword(s):  
Controlled Study ◽  
Once Daily ◽  
Randomized Controlled ◽  
Daily Dose ◽  
Cumulative Rate ◽  
Baseline Characteristics ◽  
Serum Thyroid Hormone ◽  
Thyroid Hormone Levels ◽  
Daily Dose Regimen ◽  
Clinical Trials Registry

Background. Previous studies used unequal or high daily dosages of methimazole (MMI) to compare the efficacy of once daily dose regimen (OD-MMI) with that of divided daily doses regimen (DD-MMI) in inducing euthyroidism. Objectives. To compare the efficacy of OD-MMI to that of DD-MMI using low daily dosage of MMI in inducing euthyroidism. Methods. Fifty patients with clinically nonsevere Graves’ hyperthyroidism were randomized to be treated with 15 mg/day OD-MMI or 15 mg/day DD-MMI. Results. 21 cases (84%) in OD-MMI and 23 cases (92%) in DD-MMI were eligible for analyses. During the treatment, there was no difference in baseline characteristics, serum FT3 and FT4 reductions, and cumulative rate of achieving euthyroidism (4.8% versus 4.3%, 28.6% versus 34.8%, 71.4% versus 82.6%, and 85.7% versus 87.0% at 2, 4, 8, and 12 weeks, resp.) between both regimens. Hypothyroidism developed in DD-MMI significantly more than in OD-MMI (17.4% versus 0%, p<0.05). Conclusions. Treatment with MMI at a low daily dosage of 15 mg/day OD-MMI is as effective as DD-MMI in the reduction of serum thyroid hormone levels and induction of euthyroidism. The OD-MMI regimen is preferable to the DD-MMI regimen in the treatment of clinically nonsevere Graves’ hyperthyroidism. This trial is registered with Thai Clinical Trials Registry: TCTR20170529001.

Sign in / Sign up

Export Citation Format

Share Document